Literature DB >> 17960949

Warfarin pharmacogenetics: economic considerations.

Dyfrig A Hughes, Munir Pirmohamed.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17960949     DOI： 10.2165/00019053-200725110-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  17 in total

Review 1.  The role of cost-effectiveness analysis in the era of pharmacogenomics.

Authors:  Christopher R Flowers; David Veenstra
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

2.  CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring?

Authors:  Tom Schalekamp; Gerard J J Boink; Loes E Visser; Bruno H Ch Stricker; Anthonius de Boer; Olaf H Klungel
Journal:  Clin Pharmacol Ther       Date:  2006-06       Impact factor: 6.875

Review 3.  Effect of study setting on anticoagulation control: a systematic review and metaregression.

Authors:  Carl van Walraven; Alison Jennings; Natalie Oake; Dean Fergusson; Alan J Forster
Journal:  Chest       Date:  2006-05       Impact factor: 9.410

Review 4.  Self-monitoring of oral anticoagulation: a systematic review and meta-analysis.

Authors:  C Heneghan; P Alonso-Coello; J M Garcia-Alamino; R Perera; E Meats; P Glasziou
Journal:  Lancet       Date:  2006-02-04       Impact factor: 79.321

5.  Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.

Authors:  Robert G Hart; Lesly A Pearce; Maria I Aguilar
Journal:  Ann Intern Med       Date:  2007-06-19       Impact factor: 25.391

6.  Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism.

Authors:  Clive Kearon; Jeffrey S Ginsberg; Michael J Kovacs; David R Anderson; Philip Wells; Jim A Julian; Betsy MacKinnon; Jeffrey I Weitz; Mark A Crowther; Sean Dolan; Alexander G Turpie; William Geerts; Susan Solymoss; Paul van Nguyen; Christine Demers; Susan R Kahn; Jeannine Kassis; Marc Rodger; Julie Hambleton; Michael Gent
Journal:  N Engl J Med       Date:  2003-08-14       Impact factor: 91.245

7.  The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy - a decision analysis.

Authors:  Joyce H S You; Fredric W H Chan; Raymond S M Wong; Gregory Cheng
Journal:  Thromb Haemost       Date:  2004-09       Impact factor: 5.249

Review 8.  Frequency of adverse events in patients with poor anticoagulation: a meta-analysis.

Authors:  Natalie Oake; Dean A Fergusson; Alan J Forster; Carl van Walraven
Journal:  CMAJ       Date:  2007-05-22       Impact factor: 8.262

9.  Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation.

Authors:  Elaine M Hylek; James D'Antonio; Carmella Evans-Molina; Carol Shea; Lori E Henault; Susan Regan
Journal:  Stroke       Date:  2006-03-09       Impact factor: 7.914

10.  Optimal oral anticoagulant therapy in patients with mechanical heart valves.

Authors:  S C Cannegieter; F R Rosendaal; A R Wintzen; F J van der Meer; J P Vandenbroucke; E Briët
Journal:  N Engl J Med       Date:  1995-07-06       Impact factor: 91.245
View more
  7 in total

1.  Clinician adoption of genetic testing for drug metabolizing enzymes: is patient safety the low-hanging fruit of personalized medicine?

Authors:  Harry Enchin
Journal:  AMIA Annu Symp Proc       Date:  2009-11-14

2.  A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing.

Authors:  Lisa M Meckley; James M Gudgeon; Jeffrey L Anderson; Marc S Williams; David L Veenstra
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 3.  Cardiovascular pharmacogenomics and individualized drug therapy.

Authors:  Naveen L Pereira; Richard M Weinshilboum
Journal:  Nat Rev Cardiol       Date:  2009-08-25       Impact factor: 32.419

4.  Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study.

Authors:  Andrea L Jorgensen; Sameh Al-Zubiedi; Jieying Eunice Zhang; Andrew Keniry; Anita Hanson; Dyfrig A Hughes; Diane van Eker; Lisa Stevens; Karen Hawkins; Cheng H Toh; Farhad Kamali; Ann K Daly; David Fitzmaurice; Alison Coffey; Paula R Williamson; Brian Kevin Park; Panos Deloukas; Munir Pirmohamed
Journal:  Pharmacogenet Genomics       Date:  2009-10       Impact factor: 2.089

Review 5.  Evidence to Support Inclusion of Pharmacogenetic Biomarkers in Randomised Controlled Trials.

Authors:  Danielle Johnson; Dyfrig Hughes; Munir Pirmohamed; Andrea Jorgensen
Journal:  J Pers Med       Date:  2019-09-01

6.  Impact of PCSK9, WDR12, CDKN2A, and CXCL12 Polymorphisms in Jordanian Cardiovascular Patients on Warfarin Responsiveness and Sensitivity.

Authors:  Rasheed K Ibdah; Laith N Al-Eitan; Nasr N Alrabadi; Ayah Y Almasri; Adan H Alnaamneh; Rame H Khasawneh; Mansour A Alghamdi
Journal:  Int J Gen Med       Date:  2021-01-14

7.  Effects of coagulation factor VII polymorphisms on warfarin sensitivity and responsiveness in Jordanian cardiovascular patients during the initiation and maintenance phases of warfarin therapy.

Authors:  Laith N Al-Eitan; Ayah Y Almasri; Sahar O Al-Habahbeh
Journal:  Pharmgenomics Pers Med       Date:  2019-01-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.